0% READ
FULL TEXT
INTRODUCTION
The pharmaceutical field is constantly exploring new approaches to drug delivery, with a particular focus on targeted delivery methods. Targeted delivery enhances patient safety and medication compliance. However, the conventional method is unable to fulfill individual patient needs due to their focus on mass production (Gaurkhede et al., 2021). Traditional methods, including encapsulation and compression, are expensive and struggle to produce highly complex medications. Additionally, they are ineffective in manufacturing personalized products (Tan et al., 2019). For this purpose, 3D printing, a rapidly expanding and revolutionary technology, can be employed to make additive items from electronic models (Glukhova et al., 2022). The 3D printing process involves two key steps: (1) transferring data from software to the 3D printer and (2) using the print head to repeatedly deposit material in layers, building the object one layer at a time (Ramya and Vanapalli, 2016). 3D printing technology gained significant attention in August 2015 when the FDA approved Spritam® (levetiracetam) as the first additive manufacturing tablet (Samiei, 2020). The pharmaceutical industry has recently shown a surge of interest in additive printing. This is due to 3D printing's unique capabilities, such as creating complex drug release patterns, intricate drug shapes and customized medications. Additionally, it enhances the effectiveness of drug loading into pharmaceutical products (Sen et al., 2020). 3D printing possesses several key features, including affordability, accessibility and the ability to produce objects in any conceivable shape. These potential positions 3D printing as a technology with significant probability for advancements in both the pharmaceutical and biomedical fields.2 Three-dimensional printing is a rapid prototyping technique that creates products layer by layer. This enables the production of complex internal structures, such as hollow channels, internal walls and areas with varying materials and porosities. Besides, additive manufacturing allows the dispensation of multiple drugs within a single object, a capacity beyond the reach of traditional pharmaceutical manufacturing methods (Li et al., 2018). Contemporary advancements in 3D printing technology have extended implementation in oral drug administration. This is notable because successful drug delivery requires leveraging modern technologies like 3D printing and nanotechnology while ensuring safe medication delivery (Pandey et al., 2020). In tissue engineering and drug delivery, additive printing enables the creation of intricate and personalized structures infused with medication, which is especially advantageous for pediatric and geriatric patients (Jamróz et al., 2018). 3D printing encompasses various techniques, such as Stereolithography (SLA), Fused Deposition Modeling (FDM), Powder Bed Fusion, Binder Jetting and Material Jetting. FDM is particularly notable for its versatility and affordability, making it the most commonly utilized method.
Several techniques are employed in the creation of 3D-printed objects, including Fused Deposition Modeling (FDM) (Nober et al., 2019), Binder jet 3D printers (Sen et al., 2020) Stereolithography (SLA) (Wang et al., 2016), Extrusion-based modelling (Gaurkhede et al., 2021). This review article examines how 3D printing has transformed the development of various Drug Delivery Systems (DDS), such as tablets, capsules, gels, novel dosage forms and transdermal patches. Additionally, 3D printing provides a unique capability to tackle the challenge of creating complex multi-drug tablets, where each drug is released according to a customized release profile (Khaled et al., 2015).
Current research aims to provide a comprehensive review of 3D printing technologies used in drug delivery systems. This review will cover various 3D printing methods, including Fused Deposition Modeling (FDM), Stereo Lithography (SLA) and Digital Light Processing (DLP), among others. It will delve into how these techniques are applied to develop a range of drug delivery systems, such as multi-layered tablets, hydrogels, nanoparticles, liposomes, niosomes and transdermal patches. Additionally, the review will discuss the specific functionalities and practical applications of each 3D printing method in this context.
MATERIALS AND METHODS
The study took place over four months, from February 10, 2024, to June 10, 2024. Ethical approval was granted by the Research Ethics Committee at the University of Biological and Applied Sciences (UBAS) in Lahore, Pakistan, under reference number RMEC/AM/09791, ensuring adherence to ethical standards and guidelines. This review primarily utilized PubMed and Cochrane databases. The study protocols followed the PRISMA flow statement guidelines. Research studies were identified using keywords such as '3D Printing,' 'Future Fabrication,' 3D Printing Applications'' and '2010-2024'. Additionally, various electronic databases and manual searches on Google Scholar were conducted to collect relevant studies for this review. The inclusion criteria focused on studies conducted in English and studies on 3d printing, modern dosage form fabrication and its applications between 2010 and 2024 in different world regions.
Only studies published in English were considered. The Prisma flow chart and appraisal tool for systematic review are given in Figure 1 and Table 1, respectively.
| Parameters | Study 1 (Gaurkhede et al., 2021) | Study 2 (Tan and Maniruzzaman, 2019) | Study 3 (Glukhova et al., 2022) | Study 4 (Li et al.,2018) | Study 5 (Sen et al., 2020) | Study 6 (Nober et al., 2019) | Study 7 (Wang et al., 2016) | Study 8 (Khaled et al., 2015) | Study 9 (Erkus et al., 2023) | Study 10(Petrová et al., 2024) | Study 11(Yeung et al., 2019) | Study 12 (Chen et al., 2022) | Study 13 (Bressan et al., 2019) | Study 14(Valencia et al., 2022) | Study 15 (Sharma et al., 2022) | Study 16 (Goyanes et al., 2015) | Study 17 (Pereira et al., 2019) | Study 18 (Fina et al., 2018) | Study 19 (Fina et al., 2017) | Study 20 (Cho and Jammalamadaka, 2018) | Study21 (Chan et al., 2024) | Study 22 (He et al., 2023) | Study 23 (Ballacchino et al., 2021) | Study 24 (Wang et al., 2016) | Study 25 (Arcaute and Mann, 2010) | Study 26 (Curti and Kirby, 2024) | Study 27 (Xu et al., 2020) | Study 28 (Linares et al., 2023) | Study 29 (Eosoly et al., 2010) | Study 30 (Pandav and Karanwad, 2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Are study objectives specific? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Is the study design suitable for aims? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Was the basic data adequately described? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were results internally consistent? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were the results presented for all the analyses described in the methods? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Are discussion and conclusions justified by results? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were the limitations of the study discussed? | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Is there any conflict of interest that might affect study findings? | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Parameters | Study 31 (Fina et al., 2017) (Fina et al., 2017) | Study 32 (Lekurwale and Karanwad, 2022) | Study 33 (Fina et al., 2018) | Study 34 (Adamov et al., 2022) | Study 35(Kadry et al., 2019) | Study36 (Xu et al., 2021) | Study 37 (Wu et al., 2019) | Study 38 (Yang et al., 2020) | Study 39 (Madžarević, 2021) | Study 40 (Xu et al., 2021) | Study 41 (Li et al., 2022) | Study 42 (Papadimitriou et al., 2022) | Study 43 (Xenikakis and Tsongas, 2021) | Study 44 (Cristaldi et al., 2021) | Study 45 (Cristaldi, 2020) | Study 46 (De Grandi et al., 2022) | Study 47 (He et al., 2023) | Study 48 (Tan and Maniruzzaman, 2018) | Study 49 (Cailleaux and Sanchez-Ballester, 2021) | Study 50 (Mathew et al., 2020) | Study51 (Pires et al., 2020) | Study 52(Khalid, 2022) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Are study objectives specific? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Is the study design suitable for aims? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Was the basic data adequately described? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were results internally consistent? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were the results presented for all the analyses described in the methods? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Are discussion and conclusions justified by results? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Were the limitations of the study discussed? | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Is there any conflict of interest that might affect study findings? | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
Exclusion Criteria
The exclusion criteria included:
- Conventional dosage form design.
- Traditional methods of formulation development.
- Research articles written in languages other than English.
- Studies conducted before 2010.
Data Extraction
The extracted data from the included studies comprised author details, the year of the study, the 3D printing device, its history, construction, fabrication procedure and application.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
For more information, visit: http://www.prisma-statement.org/
3D printing devices
Fused Deposition Modeling (FDM)
In 1988, Steven Scott Crump developed the Fused Deposition Modeling (FDM) method, later founding Stratasys and commercializing the process in the following year (Günaydın and Süleyman Türkmen, 2018). FDM has since become a widely used 3D printing technique for drug delivery systems (Goyanes et al., 2015).
FDM facilitates the creation of hollow objects and dosage forms with varied drug release profiles, offering high-resolution and precise dosage control through computer settings (Goyanes et al., 2015). The components of fused deposition modeling include a Filament roll from where the filament holds drug and polymer passes towards heated rollers. The heated material is released from the nozzle to a moveable base/platform, where 3D objects are prepared. The graphical representation of fused deposition modeling is shown in Figure 2.
Fused Deposition Modeling (FDM) operates by passing an extruded polymer filament through a heated coil, melting the polymer, which is then deposited onto a platform where it solidifies. By relying on these solidified layers, a 3D object is formed. FDM enables the creation of hollow objects and dosage forms with varying drug release profiles by adjusting the formulation's infill density or surface area-to-volume ratio. This technique, known as Hot-Melt Extrusion (HME), is commonly used in the pharmaceutical industry to integrate drugs within a carrier matrix at the molecular level, allowing for the development of solid solutions for drug delivery systems with higher drug-loading capacity (Goyanes et al., 2015).
Microfluidics is used for nanoparticles, with reactors essentially made from conventional materials. 3D printing is being used, with fused deposition modeling being a less expensive option (Bressan et al., 2019). Fused deposition modeling, in which an extruded polymer crosses through a heating coil. The polymer softens by heat and then is placed onto a plate to solidify. Then, layers of hardened polymer are deposited and form a 3D object. This printing method can form hollow objects and dosage forms in different drug release profiles. The final step involves adjusting the surface area-to-volume ratio or infill density of the formulation. Compared to earlier printing methods, FDM 3D printing provides higher resolution and allows for improved dosage precision, which can be readily adjusted by modifying computer settings (Goyanes et al., 2015).
Selective Laser Sintering technique (SLS)
SLS, a 3D printing technique, is utilized for the development of innovative solid dosage forms (Fina et al., 2018). At room temperature, this method is advantageous for producing objects with good resolution (Fina et al., 2017).
The study's objective is to show that SLS is easy to use to form novel solid dosage forms with instant drug release qualities to make the oral disintegrating formulations (Fina et al., 2018). The components of SLS are a Laser, scanner, recoated blade, power bed, power tank and building plate as shown in Figure 3 (Fina et al., 2017).
Copolymers and polymers were combined individually with colorant and 5% active ingredient. The powder mixtures were then printed using SLS technology to form printlet. Printlets hold active ingredients, which have recently been produced by using various 3-D printing processes called stereolithography. Drug-containing photopolymerizable polymer solution is solidified using a laser with SLA technology. At room temperature, this method has the advantage of forming objects with good resolution (Fina et al., 2017).
Stereolithography (SLA)
Stereolithography is a fast, economical, one-step method for producing multi-scale aspects and combining them with microfluidic-microneedle devices at the same time (Yeung et al., 2019). Among the various forms of 3D printing, Stereo Lithography (SLA) stands out for its capability to create objects through the formation of interconnected polymer matrices via resin cross-linking (Cho et al., 2018).
3D printing has emerged as a powerful technique for fabricating 3D nanogels. Nanogels are hydrogels formed by cross-linking nanoscopic micelles dispersed in a liquid medium. Most nanogels are produced by incorporating drug(s) or photo-initiator-loaded nanoparticles, liposomes, or nano-emulsions into hydrogels using 3D printing methods (Cho et al., 2018). To enhance the capabilities of Stereo Lithography (SLA), components typically include a resin vat, UV chamber, biocompatible resins and composite materials, as illustrated in Figure 4 (Yeung et al., 2019).
Stereolithography exhibits a vat polymerization process. In resin vat, the laser is directed to a certain depth, resulting in localized polymerization and consequent solidification. The intensity of the light source, scanning speed, exposure time, quantity of polymer and photo-initiator employed and various other factors collectively determine the energy imparted by the laser during SLA printing. Layer-by-layer solidification proceeds until a complete, three-dimensional object is produced (Wang et al., 2016). A new composite substance with added metal is necessary to enhance the SLA application and mechanical properties. Ag nanoparticles are a promising class of nanofillers for obtaining composites with optical and electrical properties, hence expanding the range of applications for SLA into domains such as biomedical or electronic.
In the manufacturing of patches, the solidification of liquid resin to obtain the desired object in the SLA method relies on photopolymerization. Solidification is continued until solid; the 3D object is manufactured (Wang et al., 2016). An SLA printer and Class IIa biocompatible resin were utilized to create a microfluidic-enabled microneedle device. The product underwent preprocessing using 3D printer preparation software and was designed using Computer-Aided Design (CAD) software. To enhance productivity and quality, the object was positioned at a 45º angle. To optimize the stiffness and strength of the microneedle patch, SLA-printed components were cleaned in isopropyl alcohol for 5 min and then cured in a UV chamber with a 405nm wavelength at 80ºC for 20 min. A single-piece, three-dimensional microfluidic device with a multi-inlet and integrated hollow microneedle array was produced using SLA 3D printing. Underneath the construction platform is an optical window through which the printer in use applies UV light, enabling additive manufacturing of the intended model through the layer-after-layer curing of photopolymer resin inside the resin tank (Yeung et al., 2019).
Digital Light Processing (DLP)
It is a 3D printing technique based on photopolymerization. By this technique, irradiation photopolymer hardens layer by layer as the sections of the model are stick out onto the liquid photopolymer’s surface by the digital micromirror element (Erkus et al., 2023).
Digital light processing is a helpful technique for producing a digital workflow for personalized medicine. There is evidence of its effectiveness in applications in biomedical areas such as dental prostheses and tissue engineering (Yang et al., 2020). The initial functional component is a digital micromirror device made of several adjustable mirror sizes of microns, as shown in Figure 5.
This method employs light sources that direct light onto photosensitive material using an array of chipsets based on optical microelectromechanical technology. A rotating mirror controls the path of light, projecting it onto photosensitive resins. The resolution of digital light processing-based 3D printing is determined by the projection plane, which is modified by the DMD (Digital Micromirror Device) and lens. Ultimately, digital light processing achieves high-resolution (Zhang et al., 2020). Microneedles were prepared with the help of a computer-aided program named Tinker CAD. After printing, every patch consisted of 36 conical microneedles measuring 1mm in diameter and 1.5 mm in height. After being changed to STL format, the design was connected to the Lumen X 3D printer. In the printing process, a solvent and resin are utilized. Following printing, the patch was gently removed, rinsed in 70% ethanol and then exposed to a UV chamber for 1 min (Petrová et al., 2024). In contrast to other techniques, DLP is less susceptible to oxygen inhibition. As compared to the rest of the 3D printing techniques, DLP provides higher resolution and faster printing (Erkus et al., 2023). Rapid modifications to the final patch’s size and shape are another merit of employing DLP printing, contrary to the conventional method (Petrová et al., 2024).
LCD-printed microfluidic devices
LCD 3D printing, combined with specially formulated ink, paves the way for anyone, anywhere, to access high-resolution formulating of ready-to-use microfluidic and organ-on-a-chip devices. This technology even holds promise for the preparation of liposomes (He et al., 2023).
The liposomes made with microfluidics have better encapsulation efficiency than other techniques (Ballacchino et al., 2021). Printer platform, printed object, resin vat, power switch, USB port, LED source, touch screen and platform securing knob as shown in Figure 6 (Ballacchino et al., 2021).
The designed microfluidic devices were used in this work to manufacture liposomes. It entails the fabrication of various microfluidic structures, particularly Y-shaped mixers, featuring different configurations with two inlets and one outlet. A continuous flow of lipids in an alcohol solution and another in a wet solution pass through separate channels. Liposome production is achieved by merging these two channels where the streams converge. Therefore, the mixing is determined by the diffusion process occurring at the boundary between liquids, resulting in the formation of micelles as the lipids precipitate in the wet solutions, followed by the formation of liposomes (Ballacchino et al., 2021).
3D-printed Reactor-in-a-Centrifuge (RIAC) device
RIAC is a simple, pump-free technique that requires a 3D-printed flow-through reactor and is powered by a standard centrifuge (Andrea et al., 2021).
The RIAC device is used to formulate liposomes and silver nanospheres, which are used in the production of nanoparticles (Andrea et al., 2021). The components used in the formulation of liposomes are the reservoir, centrifuge tube, polymer stabilizer and test tube, as shown in Figure 7 (He et al., 2023).
Another device is a 3D-printed RIAC device in which a single reservoir was pipetted with a lipid solution of 2 mL, which contained different molar ratios of stabilizer, solubilizer, surfactant, polymer stabilizer and membrane stabilizer to produce liposomes and optimize the formulation parameters. After being preheated to the appropriate temperature, Deionized water was transferred into the second reservoir. Additionally, 6 mL of water was added to the bottom of a 50 mL centrifuge tube containing the RIAC. This water addition was aimed at reducing the tendency of liposomes to aggregate. Increasing this volume beyond 6 mL would not significantly alter the properties of the liposomes. However, modifying production parameters such as time (between 1000 and 2000 cf) and centrifugal force would further decrease the concentration of liposomes in the final product (He et al., 2023).
Applications of 3d Printed Devices
Fused Deposition Modelling (FDM)
FDM provides cost-effectiveness, design flexibility and exceptional reproducibility in pharmaceutical production procedures (Tan et al., 2018). This technology aids the production of complicated geometries swiftly from digital design without any necessity of moulds or other traditional industrial procedures (Cailleaux et al., 2021). FDM printing technology can be utilized in the development of Controlled-release and floating gastroretentive tablets. Due to its accuracy, versatility and ease of use in producing various dosage forms, including implants, capsules, films and adhesives, 3D printing by fused deposition modeling contains great potential for therapeutic customization (Pires et al., 2020). Solid dispersions can enhance the solubility of APIs by utilizing suitable polymers. Combining solid dispersions with FDM offers new technological possibilities that address the challenge of low API solubility (Khalid and Billa, 2022).
Stereolithography (SLA)
SLA is used for the development of controlled-release drug delivery (Xu et al., 2020). It finds applications in the field of tissue engineering. SLA is used to develop multi-material 3-D structures with specified characteristics (Arcaute and Mann, 2010). SLA is also used for thermolabile drugs and avoids flowability issues (Arcaute et al., 2010). SLA can form printable resins (Linares et al., 2023).
Selective Laser Sintering (SLS)
SLS printers are capable of producing bilayer objects. In industries, SLS is used for different manufacturing processes, such as plastic, metallic and ceramic products. The necessity of excipients and solvents can be minimized. Also, it recycles and reprocesses feedstock. SLS is used to form porous scaffolds with intricate geometries both internally and externally. SLS devices produce SLS-mediated hollow capsular shells (Linares et al., 2023).
Digital Light Processing (DLP)
DLP is effective for establishing a digital workflow in personalized medicine, as evidenced by its applications in biomedical fields such as dental prostheses and tissue engineering. Hydrogel, microneedles and dental models can be manufactured (Pandav et al., 2024). Drug delivery systems such as nose patches, intravaginal rings, oral dosage forms, bladder devices, microneedles and dental implants can be produced with the help of DLP (Adamov et al., 2022). It is also used in computational imaging, multiplexing and hyperspectral imaging (Xu et al., 2021). Designing acrylate-based photosensitive resin through 4D printing can be done through DLP (Kadry et al., 2019).
LCD 3D Printer
Liquid Crystal Display (LCD) technology is utilized to manufacture solid oral dosage forms, where active substances can be blended with photopolymer before printing and encapsulated within solidified matrices (Wu et al., 2019). In mobile-based pharmaceutical supply systems it is clearly advantageous for patients who live far away, as it improves access to healthcare by allowing them to receive their medications directly (Madžarević and Ibrić, 2021). Liquid crystal display 3D printing helps in the formulation of different placebo moulds of VOR tablets (Xu et al., 2021). Microneedle arrays are successfully constructed employing 3D printing methods such as liquid crystal display (Papadimitriou et al., 2022). By using a liquid crystal display, the human microneedles were fabricated, which provides the accuracy that is essential for microstructures like human Microneedles (Papadimitriou et al., 2022).
Reactor in a Centrifuge (RIAC)
The efficacy and accuracy of the reactors were demonstrated through the production of inorganic and organic nanoparticles. It is used in the formulation of nanoscale liposomes within the required size range, that is, diameter (80-300 nm). It is also used to produce silver nanospheres at selected operational settings, which have significance in drug delivery for infectious and cancerous disease treatment and imaging techniques. Cationic liposomes have become a necessary DDS due to the advancement in the fields of gene therapy and mRNA-based vaccines. Due to their compatibility and effectual transfection, results have led to the development of functionalized liposomal formulation through RIAC. RIAC is used to formulate liposomes and silver nanospheres (Andrea et al., 2021). The graphical representation of the 3d printing application is illustrated in Figure 8.
CONCLUSION
This review comprehensively explored the development procedures and diverse applications of 3D printing technologies in fabricating a range of drug delivery systems. From FDM-printed controlled-release tablets to DLP-manufactured microneedles, 3D printing offers unparalleled flexibility and customization compared to traditional methods. Notably, 3D printing empowers the creation of personalized medicine, a prospect previously limited by conventional manufacturing. While challenges like high costs and complex material requirements remain, 3D printing undoubtedly presents a transformative platform for the pharmaceutical industry, paving the way for more precise, patient-centric and on-demand drug delivery systems.
